Clinical decision-making for TP53 mutant AML has traditionally relied on integration of laboratory parameters, molecular and cytogenic data, and established clinical risk scoring systems—such as the European Leukemia Net (ELN) classification for AML, National Comprehensive Cancer Network (NCCN), or the International Prognostic Scoring System (IPSS) for myelodysplastic syndrome (MDS)—to assess risk, guide prognostication, and identify potential therapies [41]. Here, TP53 is linked to myelodysplastic syndrome.